{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:40:22Z","timestamp":1789497622149,"version":"build-2803163510"},"reference-count":21,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016970","name":"Consejer\u00eda de Conocimiento, Investigaci\u00f3n y Universidad, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PAIDI P21-01002"],"award-info":[{"award-number":["PAIDI P21-01002"]}],"id":[{"id":"10.13039\/100016970","id-type":"DOI","asserted-by":"publisher"}]},{"name":"J.O. holds a \u201cNicolas Monardes\u201d research contract from the Andalusian Regional Ministry of Health","award":["C1-0003-2023"],"award-info":[{"award-number":["C1-0003-2023"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (aNSCLC). However, immune-related adverse events (irAEs) remain a clinical challenge in this context. Genetic variants acting as cis-eQTLs may predict toxicity risk, thereby enabling personalized treatment. Specifically, the interleukin 7 (IL7) rs16906115 variant has recently been implicated in ICI-related toxicity in other malignancies, like melanoma, although its role in lung cancer remains less defined. We investigated the association between the IL7 rs16906115 polymorphism, immune-related adverse events (irAEs), and survival outcomes in patients with aNSCLC receiving ICIs. Methods: This retrospective cohort study analyzed 153 patients with aNSCLC treated with ICIs (2018\u20132023) at two centers in Spain. The final analytical cohort included 124 patients with complete clinical follow-up. IL7 rs16906115 genotyping was performed using TaqMan assays. Associations between genotypes\/alleles, irAEs, and survival (PFS\/OS) were evaluated using logistic regression and Kaplan\u2013Meier analysis. A clinical\u2013genetic predictive model was developed. Results: The A allele frequency was 8.5%. Carriers of the A allele (AG\/AA genotypes) had significantly higher irAEs rates compared to GG homozygotes (OR = 3.77, 95% CI: 1.16\u201312.6, p = 0.0081). The association remained significant after multivariable adjustment (OR = 4.64, 95% CI: 1.50\u201317.2, p = 0.0203). Crucially, A-allele carriers exhibited significantly shorter Progression-Free Survival compared to non-carriers (median 6.6 vs. 10 months, p = 0.0029). The combined clinical\u2013genetic model achieved moderate predictive performance for toxicity (AUC = 0.67, 95% CI: 0.56\u20130.78) compared to clinical-only models (AUC = 0.57), stratifying patients into moderate- and high-risk groups, respectively. Conclusions: The IL7 rs16906115 polymorphism is a potential pharmacogenetic biomarker for predicting adverse events in aNSCLC immunotherapy. These findings identify the IL7 rs16906115 polymorphism as a candidate biomarker, suggesting its potential utility as an exploratory tool for risk stratification that warrants further validation.<\/jats:p>","DOI":"10.3390\/jcm15041486","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:09:32Z","timestamp":1770998972000},"page":"1486","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of IL7 rs16906115 Polymorphism with Immune-Related Adverse Events in Patients with Advanced Lung Cancer Undergoing Immunotherapy"],"prefix":"10.3390","volume":"15","author":[{"given":"Andrea","family":"Gonz\u00e1lez-Hern\u00e1ndez","sequence":"first","affiliation":[{"name":"Facultad de Medicina, Universidad de M\u00e1laga (UMA), 29071 Malaga, Spain"},{"name":"Laboratorio de Investigaci\u00f3n Traslacional en C\u00e1ncer de Cabeza y Cuello, Centro de Investigaci\u00f3n y Terapias Avanzadas del C\u00e1ncer (CITAC), 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0069-5660","authenticated-orcid":false,"given":"Guillermo","family":"Paz-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Facultad de Medicina, Universidad de M\u00e1laga (UMA), 29071 Malaga, Spain"},{"name":"Estructura Com\u00fan de Apoyo a la Investigaci\u00f3n de Bioinform\u00e1tica, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga-Plataforma BIONAND (IBIMA-Plataforma Bionand), 29590 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5664-5535","authenticated-orcid":false,"given":"Beatriz","family":"Mart\u00ednez-G\u00e1lvez","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Virgen de la Victoria, Grupo B-05 Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga-Plataforma BIONAND (IBIMA-Plataforma Bionand), 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Vaca","family":"Paniagua","sequence":"additional","affiliation":[{"name":"Laboratorio Nacional en Salud: Diagn\u00f3stico Molecular y Efecto Ambiental en Enfermedades Cr\u00f3nico-Degenerativas, Facultad de Educaci\u00f3n Superior Iztacala, Tlalnepantla 54090, Mexico"},{"name":"Unidad de Biomedicina, Facultad de Educaci\u00f3n Superior, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Tlalnepantla 54090, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Barrag\u00e1n","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Virgen de la Victoria, Grupo B-05 Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga-Plataforma BIONAND (IBIMA-Plataforma Bionand), 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7204-0800","authenticated-orcid":false,"given":"Elisabeth","family":"P\u00e9rez-Ruiz","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Regional de M\u00e1laga, Grupo B-05 Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga-Plataforma BIONAND (IBIMA-Plataforma Bionand), 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Carlos","family":"Benitez","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Virgen de la Victoria, Grupo B-05 Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga-Plataforma BIONAND (IBIMA-Plataforma Bionand), 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rueda-Dominguez","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Virgen de la Victoria, Grupo B-05 Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga-Plataforma BIONAND (IBIMA-Plataforma Bionand), 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-4711","authenticated-orcid":false,"given":"Javier","family":"Oliver","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Virgen de la Victoria, Grupo B-05 Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga-Plataforma BIONAND (IBIMA-Plataforma Bionand), 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non\u2013Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, Activity, and Immune Correlates of Anti\u2013PD-1 Antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and Treatment Specific Incidence Rates of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab: Long-Term Outcomes from a Multi-Institutional Analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Queirolo, P., Dozin, B., Morabito, A., Banelli, B., Piccioli, P., Fava, C., Leo, C., Carosio, R., Laurent, S., and Fontana, V. (2017). Association of CTLA-4 Gene Variants with Response to Therapy and Long-Term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00386"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1038\/s41467-021-23661-4","article-title":"Genetic Variation Associated with Thyroid Autoimmunity Shapes the Systemic Immune Response to PD-1 Checkpoint Blockade","volume":"12","author":"Khan","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1479-5876-11-75","article-title":"Gene Expression Profiling of Whole Blood in Ipilimumab-Treated Patients for Identification of Potential Biomarkers of Immune-Related Gastrointestinal Adverse Events","volume":"11","author":"Shahabi","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1182\/blood.V99.11.3892","article-title":"Interleukin-7: From Bench to Clinic","volume":"99","author":"Fry","year":"2002","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ng2068","article-title":"Robust Associations of Four New Chromosome Regions from Genome-Wide Analyses of Type 1 Diabetes","volume":"39","author":"Todd","year":"2007","journal-title":"Nat. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"International Multiple Sclerosis Genetics Consortium, Hafler, D.A., Compston, A., Sawcer, S., Lander, E.S., Daly, M.J., de Jager, P.L., de Bakker, P.I.W., Gabriel, S.B., and Mirel, D.B. (2007). Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study. N. Engl. J. Med., 357, 851\u2013862.","DOI":"10.1056\/NEJMoa073493"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nri2023","article-title":"Interleukin-7 Receptor Expression: Intelligent Design","volume":"7","author":"Mazzucchelli","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_13","first-page":"E1761","article-title":"Soluble IL7R\u03b1 Potentiates IL-7 Bioactivity and Promotes Autoimmunity","volume":"110","author":"Highfill","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/ng2103","article-title":"Interleukin 7 Receptor \u03b1 Chain (IL7R) Shows Allelic and Functional Association with Multiple Sclerosis","volume":"39","author":"Gregory","year":"2007","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41591-022-02095-5","article-title":"IL7 Genetic Variation and Toxicity to Immune Checkpoint Blockade in Patients with Melanoma","volume":"28","author":"Taylor","year":"2022","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1038\/s41591-022-02094-6","article-title":"Germline Variants Associated with Toxicity to Immune Checkpoint Blockade","volume":"28","author":"Groha","year":"2022","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/hepr.14092","article-title":"Evaluation of the Associations of Interlukin-7 Genetic Variants with Toxicity and Efficacy of Immune Checkpoint Inhibitors: A Replication Study of a Japanese Population, Based on the Findings of a European Genome-Wide Association Study","volume":"54","author":"Miyamoto","year":"2024","journal-title":"Hepatol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/oncolo\/oyae181.003","article-title":"22 Association of a Germline Single Nucleotide Polymorphism (SNP) in the Interleukin-7 (IL7) Gene with Immune-Related Adverse Events (irAEs)","volume":"29","author":"Saad","year":"2024","journal-title":"Oncologist"},{"key":"ref_19","first-page":"37","article-title":"Interleukin-7 Risk Allele, Lymphocyte Counts, and Autoantibodies for Prediction of Risk of Immune-Related Adverse Events in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma","volume":"103","author":"Takada","year":"2024","journal-title":"Oncology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non\u2013Small-Cell Lung Cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"The 1000 Genomes Project Consortium (2015). A Global Reference for Human Genetic Variation. Nature, 526, 68\u201374.","DOI":"10.1038\/nature15393"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1486\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:30:55Z","timestamp":1771000255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15041486"],"URL":"https:\/\/doi.org\/10.3390\/jcm15041486","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]}}}